Synthesis of site‐specific Fab‐drug conjugates using ADP‐ribosyl cyclases
Protein Science · 2024
DOI: 10.1002/pro.4924 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Science, 2024. Verfasst von Hyo Sun Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern Califor…. Hauptthemen laut MEDLINE: Antigens, CD, NAD+ Nucleosidase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIBIB NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Targeted delivery of small‐molecule drugs via covalent attachments to monoclonal antibodies has proved successful in clinic. For this purpose, full‐length antibodies are mainly used as drug‐carrying vehicles. Despite their flexible conjugation sites and versatile biological activities, intact immunoglobulins with conjugated drugs, which feature relatively large molecular weights, tend to have restricted tissue distribution and penetration and low fractions of payloads. Linking small‐molecule therapeutics to other formats of antibody may lead to conjugates with optimal properties. Here, we designed and synthesized ADP‐ribosyl cyclase‐enabled fragment antigen‐binding (Fab) drug conjugates (ARC‐FDCs) by utilizing CD38 catalytic activity. Through rapidly forming a stable covalent bond with a nicotinamide adenine dinucleotide (NAD + )‐based drug linker at its active site, CD38 genetically fused with Fab mediates robust site‐specific drug conjugations via enzymatic reactions. Generated ARC‐FDCs with defined drug‐to‐Fab ratios display potent and antigen‐dependent cytotoxicity against breast cancer cells. This work demonstrates a new strategy for developing site‐specific FDCs. It may be applicable to different antibody scaffolds for therapeutic conjugations, leading to novel targeted agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
- Department of Chemistry, University of California, Irvine, Irvine, California, USA.
- Titus Family Department of Clinical Pharmacy, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.
- Department of Chemistry, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, California, USA.
- Research Center for Liver Diseases, University of Southern California, Los Angeles, California, USA.
ORCID-Profile: Yong Zhang
Förderung
- NCI NIH HHS
- NIBIB NIH HHS
- NIGMS NIH HHS
- National Institute of General Medical Sciences
- University of Southern California
- National Cancer Institute
- National Institute of Biomedical Imaging and Bioengineering
Zitieren
APA
Kim, H. S., Hariri, K., Zhang, X. N., Chen, L. C., Katz, B. B., Pei, H., Louie, S. G., & Zhang, Y. (2024). Synthesis of site‐specific Fab‐drug conjugates using ADP‐ribosyl cyclases. Protein Science. https://doi.org/10.1002/pro.4924
Vancouver
Kim HS, Hariri K, Zhang XN, Chen LC, Katz BB, Pei H, et al. Synthesis of site‐specific Fab‐drug conjugates using ADP‐ribosyl cyclases. Protein Science. 2024. doi:10.1002/pro.4924
BibTeX
@article{Kim2024,
author = {Kim, Hyo Sun and Hariri, Kimia and Zhang, Xiao-Nan and Chen, Liang-Chieh and Katz, Benjamin B and Pei, Hua and Louie, Stan G and Zhang, Yong},
title = {Synthesis of site‐specific Fab‐drug conjugates using ADP‐ribosyl cyclases},
journal = {Protein Science},
year = {2024},
doi = {10.1002/pro.4924}
}
EUVIMED